Alnylam Pharmaceuticals is constructing a new drug substance manufacturing and cGMP warehouse facility in Norton, Massachusetts, US. The company broke…
In February 2018, Ferring Pharmaceuticals announced plans to build a new biotechnology centre at its headquarters in Saint-Prex, Switzerland.
The company plans to invest more than CHF30m ($32.06m) in the centre over the next three years. The facility will enable the company to expand its biologics capabilities.
The first lab of the biotech centre is expected to be operational in 2019, while production of the first batch of biologics is expected to commence in 2020.
Details of Ferring’s new biotechnology centre
Currently in the engineering design phase, the new Ferring biotech centre will be built using more than 2,000m² of existing infrastructure.
The facility will be used to develop biologic therapies in the areas of reproductive medicine, women’s health, gastroenterology and urology. It will discover and develop monoclonal antibodies (mAb), as well as manufacture biologics.
The centre will also produce the active pharmaceutical ingredients (API) for Ferring’s fertility medicine Rekovelle® (follitropin delta).
Saint-Prex manufacturing site details
Ferring’s existing Saint-Prex manufacturing site covers an area of 23,000m² and comprises production, packaging and administration facilities.
Opened in 2006, the Swiss plant manufactures two products for the gastroenterology and urology markets. The gastroenterology product is used to treat inflammatory bowel diseases such as ulcerative colitis and Crohn’s disease, while the urology product is used to treat bedwetting in children and nocturia in adults.
The Saint-Prex manufacturing plant also serves as the main site for the company’s packaging activities. It packs more than 60% of Ferring’s products and also produces reference samples for more than a thousand finished products and two million boxes a month.
Details of the products manufactured at the biotech centre
Used for fertility treatment, Rekovelle® is the first recombinant follicle stimulating hormone (FSH) derived from a human cell line. The product is administered based on a woman’s serum anti-Mullerian hormone (AMH) level and body weight.
Ferring’s Israel-based subsidiary, Bio-Technology General (BTG), is currently producing the API for Rekovelle®. The API will continue to be manufactured at BTG after the opening of the new biotech centre to ensure continuity of supply for patients worldwide.
Marketing commentary on Ferring Pharmaceuticals
Founded in 1950, Ferring Pharmaceuticals is a privately-owned research-based speciality biopharmaceutical company. The company is headquartered in Saint-Prex, Switzerland.
The company has manufacturing sites in 11 countries, including Argentina, China, Czech Republic, Denmark and Germany. It also has ten research and development (R&D) centres in China, Denmark, India, Israel, Japan, Scotland, Switzerland and the US.
Ferring manufactures products in the areas of reproductive medicine, urology and gastroenterology and also specialises in peptide development and endocrine research. More than a third of the company’s investment in R&D is directed towards developing novel drugs for mothers and babies.
The company employs more than 6,500 people worldwide and markets its products and treatments in 110 countries. The company recorded revenues of €1.9bn ($2.27bn) in 2017.
Neopharma opened a pharmaceutical plant in Abu Dhabi, United Arab Emirates, in July 2003. The plant then entered a three-month…
French pharmaceutical company Sanofi’s manufacturing plant in Goa, India, is located in the Verna Industrial Park, owned by Sanofi’s Indian…
GlaxoSmithKline (GSK) began construction of an oral solid-dose manufacturing plant at the Vemgal Industrial Area in India in September 2015.…